Pfizer

Pfizer

Yahoo Finance • 2 hours ago

Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company. Continue Reading... Full story

Yahoo Finance • 3 hours ago

These 6 High-Yield Dividends May Be Too Good to Be True

Quick Read Altria posted negative quarterly operating cash flow against $1.5B in dividend outflows, while Pfizer's $0.77 EPS can't cover its $1.72 annual payout. When executives emphatically insist a dividend is safe under obvious stress,... Full story

Yahoo Finance • 5 hours ago

Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year

Quick Read Lilly's incretin franchise hit ~$15B in a single quarter while LLY shares surged 56% over the past year, leaving PFE trading at just 9x forward earnings with a 6.22% yield. Retatrutide's BLA filing in Q1 2027 across obesity, sl... Full story

Yahoo Finance • 8 hours ago

3 Dividend Stocks Trading Cheap Enough to Buy Meaningful Stakes for Under $1,000

Quick Read AT&T yields 4.37% and Verizon yields 5.78%, both with covered dividends. Verizon has raised its payout for 20 consecutive years. Pfizer leads the group with a 6.18% yield at ~$28 per share, but GAAP earnings are thin, and cover... Full story

Yahoo Finance • 11 hours ago

Pfizer (PFE) Stock May Be Overvalued After Overseas Pricing Deal

Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the q... Full story

Yahoo Finance • 12 hours ago

Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue

Company Logo Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough The... Full story

Yahoo Finance • yesterday

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?

Picking a solid dividend stock to own for the long haul isn't necessarily easy. Balancing safety and dividend income can make it challenging to find the right stock to own, one that offers a fairly high yield, which isn't too risky. If the... Full story

Yahoo Finance • yesterday

Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts

NEW YORK, September 22, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 3, 2026. T... Full story

Yahoo Finance • yesterday

MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going

Shares of Moderna MRNA rose 12% yesterday, even climbing to a new 52-week high of $176.86. The rally came as investors digested the company's announcement that it will present detailed data from the phase III INTerpath-001 study on intisme... Full story

Yahoo Finance • yesterday

Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline

Key Points Interested in Pfizer Inc.? Here are five stocks we like better. Pfizer is reducing its reliance on COVID-19 products while reallocating resources toward newer and acquired medicines, vaccines and oncology products. COVID-relate... Full story

Yahoo Finance • yesterday

Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon

Quick Read Citigroup's Geoff Meacham targets $1,600 for LLY, representing 37% upside, anchored by Mounjaro and Zepbound's combined $14.9B single-quarter revenue. Novo Nordisk dropped 8% in one session after its post-Wegovy update disappoi... Full story

Yahoo Finance • yesterday

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

Dividend stocks are always great additions to a portfolio, as they offer investors the opportunity to earn passive income during any economic or market environment. This may compensate for weakness in your portfolio during tough market tim... Full story

Yahoo Finance • yesterday

Capitalize on the Orphan Drug Revenue Shift: Benchmark Novartis, Roche, Pfizer, Sanofi and AstraZeneca to Secure High-Value Growth Before Rivals Move First

Company Logo Orphan drug demand is rising as genomics, biologics and personalized therapies advance, aided by faster approvals, government incentives, advocacy and improved rare-disease diagnosis. Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE)... Full story

Yahoo Finance • 2 days ago

2 Large-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

2 Large-Cap Stocks to Keep an Eye On and 1 Facing Headwinds Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much... Full story

Yahoo Finance • 2 days ago

Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

DelveInsight Business Research LLP The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokima... Full story

Yahoo Finance • 2 days ago

Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer

Merck MRK announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ("CHMP") has issued a positive opinion recommending approval of a combination of its blockbuster PD-L1 inhibitor, Keytruda (pembr... Full story

Yahoo Finance • 2 days ago

Huge News For Pfizer Stock Fans

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) will share part of any additional revenue generated from higher drug prices overseas with the U.S. Department of Health and Human Services, according to a Sept. 19 report. The p... Full story

Yahoo Finance • 3 days ago

Pfizer to share higher overseas drug revenue with U.S. under new HHS contract: report

[Pfizer sign outside a corporate office building on a sunny day] VIDOK/iStock Unreleased via Getty Images * The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer (PFE [https://seekingalpha.... Full story

Yahoo Finance • 3 days ago

Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?

The past few years have been challenging for Pfizer (NYSE: PFE). The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the an... Full story

Yahoo Finance • 5 days ago

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story